{
    "clinical_study": {
        "@rank": "104032", 
        "arm_group": {
            "arm_group_label": "Patients", 
            "description": "Patients with metastatic colorectal cancer treated with chemotherapy"
        }, 
        "biospec_descr": {
            "textblock": "Urine and exfoliated oral mucosa cells"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Observational, non randomized study aimed at measuring the effect of chemotherapy in the\n      urinary concentrations of physiological modified nucleosides in 30 patients with metastatic\n      colorectal cancer."
        }, 
        "brief_title": "\"Cancersensor\" Chemotherapy", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-confirmed metastatic colorectal cancer;\n\n          -  0 to 3 prior chemotherapy lines;\n\n          -  Signed informed consent;\n\n          -  Good understanding of the protocol and of the follow-up;\n\n          -  Estimated life expectancy exceeding 3 months;\n\n          -  At least one measurable metastatic lesion (RECIST criteria);\n\n          -  Performance Status (WHO) of 0 to 2;\n\n          -  Good haematological, hepatic and renal functions.\n\n        Exclusion Criteria:\n\n          -  More than 2 surgical resections of metastases from colorectal cancer;\n\n          -  Poor performance status (>2);\n\n          -  Poor haematological, hepatic or renal functions;\n\n          -  Uncontrolled chronic disease;\n\n          -  Serious unhealed wound, ulcer or fracture within the previous month;\n\n          -  Clinical or laboratory finding suggesting possible abnormalities in nucleosides\n             urinary excretion;\n\n          -  Pregnancy or breast-feeding during the previous month;\n\n          -  Transmeridian trip of more than 4 time zones within the prior 2 weeks;\n\n          -  Person with legal restriction to participate into clinical research, according to the\n             current law in France."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic colorectal cancer treated at the Department of Medical Oncology\n        of Paul Brousse Hospital"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693861", 
            "org_study_id": "C11-59", 
            "secondary_id": "2012-A00168-35"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Colorectal", 
            "Cancer", 
            "Metastatic", 
            "Chronotherapy", 
            "Urine", 
            "Nucleosides", 
            "Chemotherapy", 
            "Treated with chemotherapy"
        ], 
        "lastchanged_date": "September 24, 2012", 
        "location": {
            "contact": {
                "email": "sandrine.dulong@inserm.fr", 
                "last_name": "Sandrine Dulong, PhD", 
                "phone": "+33149583479"
            }, 
            "contact_backup": {
                "email": "abdoulaye.karaboue@inserm.fr", 
                "last_name": "Abdoulaye Karabou\u00e9, MD", 
                "phone": "+33145593553"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "zip": "94807"
                }, 
                "name": "Paul Brousse Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Francis L\u00e9vi, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pasquale Innominato, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : Effect of Chemotherapy on Cancerous Proliferation Based on the Dynamic Excretion of Urinary Nucleosides.", 
        "other_outcome": {
            "description": "Measurement of modified nucleosides, cortisol and 6-sulfatoxymelatonin concentration in urine samples before and after chemotherapy\n1 saliva sample Measurement of Clock genes polymorphisms expression", 
            "measure": "Identification of modified nucleosides as biomarkers for colorectal cancer", 
            "safety_issue": "No", 
            "time_frame": "17 days"
        }, 
        "overall_contact": {
            "email": "francis.levi@inserm.fr", 
            "last_name": "Francis L\u00e9vi, MD PhD", 
            "phone": "+33145593595"
        }, 
        "overall_contact_backup": {
            "email": "sandrine.dulong@inserm.fr", 
            "last_name": "Sandrine Dulong, PhD", 
            "phone": "+33149583479"
        }, 
        "overall_official": {
            "affiliation": "INSERM CNRS AP-HP Universit\u00e9 Paris Sud", 
            "last_name": "Francis L\u00e9vi, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1 urine sample per day 3 days before and 14 days after beginning of chemotherapy Measurement of modified nucleosides, cortisol and 6-sulfatoxymelatonin concentration\n1 saliva sample : Measurement of Clock genes polymorphisms expression", 
            "measure": "Effect of chemotherapy on urinary excretion of modified nucleosides", 
            "safety_issue": "No", 
            "time_frame": "17 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}